$2.33
8.27% yesterday
Nasdaq, Aug 19, 10:11 pm CET
ISIN
KYG7S53R1049
Symbol
PROK

Prokidney Stock price

$2.33
-0.89 27.64% 1M
+0.76 48.41% 6M
+0.64 37.87% YTD
-0.07 2.92% 1Y
-4.27 64.70% 3Y
-7.78 76.95% 5Y
-7.78 76.95% 10Y
-7.78 76.95% 20Y
Nasdaq, Closing price Tue, Aug 19 2025
-0.21 8.27%
ISIN
KYG7S53R1049
Symbol
PROK
Industry

Key metrics

Basic
Market capitalization
$747.5m
Enterprise Value
$452.8m
Net debt
positive
Cash
$294.7m
Shares outstanding
292.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1,410.3 | 4,779.4
EV/Sales
854.4 | 2,895.4
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-225.6%
Return on Equity
6.2%
ROCE
-52.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$530.0k | $156.4k
EBITDA
$-175.5m | $-178.4m
EBIT
$-181.6m | $-189.1m
Net Income
$-72.5m | $-164.9m
Free Cash Flow
$-146.6m
Growth (TTM | estimate)
Revenue
- | 95.5%
EBITDA
-17.5% | -3.2%
EBIT
-18.0% | -6.0%
Net Income
-87.4% | -169.4%
Free Cash Flow
4.3%
Margin (TTM | estimate)
Gross
-
EBITDA
-33,304.7% | -114,043.8%
EBIT
-34,467.0%
Net
-13,752.2% | -105,416.1%
Free Cash Flow
-27,814.0%
More
EPS
$-0.6
FCF per Share
$-0.5
Short interest
8.0%
Employees
204
Rev per Employee
$0.0
Show more

Is Prokidney a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

Prokidney Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Prokidney forecast:

8x Buy
62%
4x Hold
31%
1x Sell
8%

Analyst Opinions

13 Analysts have issued a Prokidney forecast:

Buy
62%
Hold
31%
Sell
8%

Financial data from Prokidney

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.53 0.53
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 58 58
36% 36%
10,942%
- Research and Development Expense 124 124
12% 12%
23,430%
-176 -176
17% 17%
-33,117%
- Depreciation and Amortization 6.13 6.13
35% 35%
1,157%
EBIT (Operating Income) EBIT -182 -182
18% 18%
-34,272%
Net Profit -72 -72
87% 87%
-13,674%

In millions USD.

Don't miss a Thing! We will send you all news about Prokidney directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Prokidney Stock News

Neutral
GlobeNewsWire
7 days ago
WINSTON-SALEM, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapeutics company focused on chronic kidney disease (CKD), today reported financial results for the second quarter ended June 30, 2025, and provided regulatory and clinical updates.
Positive
The Motley Fool
29 days ago
If you're looking for stocks that can make dramatic movements in a short time frame, the biotechnology space has what you crave. At the end of June, ProKidney (PROK 2.06%) stock was languishing at less than $1 per share.
Positive
The Motley Fool
about one month ago
Biotech stocks can be risky but exciting investments because they can soar quickly on positive news, such as a drug approval or simply the hope that they may soon have an approved treatment. They can drop just as quickly on negative news.
More Prokidney News

Company Profile

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease (CKD), shifting the emphasis away from management of kidney failure, to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells (SRCs) prepared from a patient's own, autologous, renal cells. The company is headquartered in Winston-Salem, NC.

Head office Cayman Islands
CEO Bruce Culleton
Employees 204
Founded 2015
Website prokidney.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today